Taken together, these results indicate that the loss of TGFβ tumor-suppressive responses in patients harboring MEN1 mutations leading to MEN1 degradation could be circumvented by blocking the proteasome degradation pathway, thereby offering new therapeutic opportunities for patients with melanoma. The gene discussed is MEN1; the disease is melanoma.